242 related articles for article (PubMed ID: 33823840)
21. MUC1, MUC2, MUC5AC, and MUC6 in colorectal cancer: expression profiles and clinical significance.
Betge J; Schneider NI; Harbaum L; Pollheimer MJ; Lindtner RA; Kornprat P; Ebert MP; Langner C
Virchows Arch; 2016 Sep; 469(3):255-65. PubMed ID: 27298226
[TBL] [Abstract][Full Text] [Related]
22. Loss of MUC2 expression predicts disease recurrence and poor outcome in colorectal carcinoma.
Elzagheid A; Emaetig F; Buhmeida A; Laato M; El-Faitori O; Syrjänen K; Collan Y; Pyrhönen S
Tumour Biol; 2013 Apr; 34(2):621-8. PubMed ID: 23179399
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of low CDX2 expression in colorectal cancers with a high stromal content - a short report.
Sandberg TP; Sweere I; van Pelt GW; Putter H; Vermeulen L; Kuppen PJ; Tollenaar RAEM; Mesker WE
Cell Oncol (Dordr); 2019 Jun; 42(3):397-403. PubMed ID: 30847807
[TBL] [Abstract][Full Text] [Related]
24. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Stanisavljević L; Myklebust MP; Leh S; Dahl O
Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Value of CDX2 and Villin Expression in Advanced Stage Colorectal Carcinoma.
Altintas S; Bayrak M; Altintas Y
J Coll Physicians Surg Pak; 2019 Nov; 29(11):1057-1061. PubMed ID: 31659962
[TBL] [Abstract][Full Text] [Related]
26. Lymph node CEA and MUC2 mRNA as useful predictors of outcome in colorectal cancer.
Ohlsson L; Israelsson A; Öberg Å; Palmqvist R; Stenlund H; Hammarström ML; Hammarström S; Lindmark G
Int J Cancer; 2012 Apr; 130(8):1833-43. PubMed ID: 21618511
[TBL] [Abstract][Full Text] [Related]
27. Concomitant expression patterns of CDX2 and SATB2 as prognostic factors in stage III colorectal cancers.
Lee JA; Park HE; Jin HY; Jin L; Cho NY; Bae JM; Kim JH; Kang GH
Ann Diagn Pathol; 2024 Aug; 71():152289. PubMed ID: 38555678
[TBL] [Abstract][Full Text] [Related]
28. Lysosomal acid phosphatase 2 is an unfavorable prognostic factor but is associated with better survival in stage II colorectal cancer patients receiving chemotherapy.
Lee YC; Su CY; Lin YF; Lin CM; Fang CY; Lin YK; Hsiao M; Chen CL
Oncotarget; 2017 Feb; 8(7):12120-12132. PubMed ID: 28076332
[TBL] [Abstract][Full Text] [Related]
29. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
Dalerba P; Sahoo D; Paik S; Guo X; Yothers G; Song N; Wilcox-Fogel N; Forgó E; Rajendran PS; Miranda SP; Hisamori S; Hutchison J; Kalisky T; Qian D; Wolmark N; Fisher GA; van de Rijn M; Clarke MF
N Engl J Med; 2016 Jan; 374(3):211-22. PubMed ID: 26789870
[TBL] [Abstract][Full Text] [Related]
30. Quantitative analysis of CDX2 protein expression improves its clinical utility as a prognostic biomarker in stage II and III colon cancer.
den Uil SH; de Wit M; Slebos RJC; Delis-van Diemen PM; Sanders J; Piersma SR; Pham TV; Coupé VMH; Bril H; Stockmann HBAC; Jimenez CR; Meijer GA; Fijneman RJA
Eur J Cancer; 2021 Feb; 144():91-100. PubMed ID: 33341450
[TBL] [Abstract][Full Text] [Related]
31. Dynamics of SOX2 and CDX2 Expression in Barrett's Mucosa.
Barros R; Pereira D; Callé C; Camilo V; Cunha AI; David L; Almeida R; Dias-Pereira A; Chaves P
Dis Markers; 2016; 2016():1532791. PubMed ID: 27766003
[TBL] [Abstract][Full Text] [Related]
32. The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study.
He EY; Hawkins NJ; Mak G; Roncolato F; Goldstein D; Liauw W; Clingan P; Chin M; Ward RL
Oncologist; 2016 May; 21(5):618-25. PubMed ID: 27009937
[TBL] [Abstract][Full Text] [Related]
33. Co-expression of CDX2 and MUC2 in gastric carcinomas: correlations with clinico-pathological parameters and prognosis.
Roessler K; Mönig SP; Schneider PM; Hanisch FG; Landsberg S; Thiele J; Hölscher AH; Dienes HP; Baldus SE
World J Gastroenterol; 2005 Jun; 11(21):3182-8. PubMed ID: 15929165
[TBL] [Abstract][Full Text] [Related]
34. Expression of the hMLH1 gene is a possible predictor for the clinical response to 5-fluorouracil after a surgical resection in colorectal cancer.
Ide T; Kitajima Y; Ohtaka K; Mitsuno M; Nakafusa Y; Miyazaki K
Oncol Rep; 2008 Jun; 19(6):1571-6. PubMed ID: 18497967
[TBL] [Abstract][Full Text] [Related]
35. CDX2 controls genes involved in the metabolism of 5-fluorouracil and is associated with reduced efficacy of chemotherapy in colorectal cancer.
Delhorme JB; Bersuder E; Terciolo C; Vlami O; Chenard MP; Martin E; Rohr S; Brigand C; Duluc I; Freund JN; Gross I
Biomed Pharmacother; 2022 Mar; 147():112630. PubMed ID: 35051860
[TBL] [Abstract][Full Text] [Related]
36. Differential Expression of β-Catenin, EGFR, CK7, CK20, MUC1, MUC2, and CDX2 in Intestinal and Pancreatobiliary-Type Ampullary Carcinomas.
Perysinakis I; Minaidou E; Leontara V; Mantas D; Sotiropoulos GC; Tsipras H; Zografos GN; Margaris I; Kouraklis G
Int J Surg Pathol; 2017 Feb; 25(1):31-40. PubMed ID: 27543509
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of lymphovascular invasion in stage II colorectal cancer patients with an inadequate examination of lymph nodes.
Gao Z; Cao H; Xu X; Wang Q; Wu Y; Lu Q
World J Surg Oncol; 2021 Apr; 19(1):125. PubMed ID: 33866973
[TBL] [Abstract][Full Text] [Related]
38. The prognostic potential of CDX2 in colorectal cancer: Harmonizing biology and clinical practice.
Badia-Ramentol J; Gimeno-Valiente F; Duréndez E; Martínez-Ciarpaglini C; Linares J; Iglesias M; Cervantes A; Calon A; Tarazona N
Cancer Treat Rev; 2023 Dec; 121():102643. PubMed ID: 37871463
[TBL] [Abstract][Full Text] [Related]
39. Lymphocytic infiltration in stage II microsatellite stable colorectal tumors: A retrospective prognosis biomarker analysis.
Sanz-Pamplona R; Melas M; Maoz A; Schmit SL; Rennert H; Lejbkowicz F; Greenson JK; Sanjuan X; Lopez-Zambrano M; Alonso MH; Qu C; McDonnell KJ; Idos GE; Vignali M; Emerson R; Fields P; Guinó E; Santos C; Salazar R; Robins HS; Rennert G; Gruber SB; Moreno V
PLoS Med; 2020 Sep; 17(9):e1003292. PubMed ID: 32970670
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of CDX2 immunoexpression in poorly differentiated clusters of colorectal carcinoma.
Reggiani Bonetti L; Lionti S; Vitarelli E; Barresi V
Virchows Arch; 2017 Dec; 471(6):731-741. PubMed ID: 28819729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
